PRTC
PureTech Health PLC Sponsored ADR · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website uretechhealth.com
- Employees(FY) 111
- ISIN US7462371060
Performance
-0.79%
1W
+0.45%
1M
+20.22%
3M
+25.28%
6M
-1.88%
YTD
+4.83%
1Y
Profile
PureTech Health plc, a clinical stage biotherapeutics company, engages in the discovery, development, and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, currently under Phase 3 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, to inhibit the activity of galectin-9 for treating solid tumors and hematological malignancies. It is also developing LYT-300, an oral allopregnanolone, currently completed Phase 1 stage, to treat depression, anxiety, and related indications; and LYT-310, an oral cannabidiol, currently under preclinical stage, to treat epilepsies and other neurological indications. In addition, the company is developing LYT-503/IMB-150, a non-opioid inflammation targeted disease immunomodulation for the potential treatment of interstitial cystitis, or bladder pain syndrome; and Glyph technology platform, a lymphatic-targeting chemistry platform, which leverages the body's natural lipid absorption and transports the process to orally administer drugs via the lymphatic system. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Investment Analysis Report: PRTC
Overview:
PRTC is a company operating in the Health Technology sector, specifically in the Biotechnology industry. The company has a market capitalization of $620,884,402. In this report, we will conduct a detailed analysis of PRTC's financial health, valuation, earnings and revenue growth, profitability, operati...
Technical Analysis of PRTC 2024-05-10
Overview:
In analyzing the technical indicators for PRTC over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive assessment of the stock's potential price movement. By examining these key factors, we aim to offer valuable insights and predictions for the next few days.
Trend Anal...
Recent News & Updates
- 2024-05-09 07:05
- 2024-05-08 19:05
- 2024-05-07 07:05
- 2024-05-06 19:05
- 2024-04-30 08:37
- 2024-04-29 20:37
- 2024-04-25 05:22
- 2024-04-24 17:22
- 2024-04-18 02:00
PureTech Health: Notice of Results(Business Wire)
- 2024-04-17 14:00
PureTech Health: Notice of Results(Businesswire)
- 2024-04-16 07:00
- 2024-04-15 19:00
- 2024-04-11 07:00
- 2024-04-10 19:00
- 2024-04-09 08:19
PureTech launches Seaport, hoping to create Karuna 2.0(BioPharma Dive)
- 2024-04-09 02:00
- 2024-04-08 14:00
- 2024-04-02 08:50
- 2024-04-01 20:50
- 2024-03-19 03:00
PureTech Proposes $100 Million Capital Return(Business Wire)
- 2024-03-18 15:00
PureTech Proposes $100 Million Capital Return(Businesswire)
- 2024-03-18 09:52
- 2024-03-17 21:52
- 2024-03-13 07:00
- 2024-03-12 19:00
- 2024-02-27 07:00
PureTech to Present at Two Upcoming Investor Conferences(Business Wire)
- 2024-02-27 02:00
- 2024-02-26 18:00
PureTech to Present at Two Upcoming Investor Conferences(Businesswire)
- 2024-02-26 13:00
- 2024-02-15 09:35
Page 1 of 3
previousnext